Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
89% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MDXG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MDXG' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.80
MDXG's Equity to Asset is ranked higher than
76% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MDXG: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
MDXG' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.82 Max: 0.89
Current: 0.8
0.44
0.89
Interest Coverage No Debt
MDXG's Interest Coverage is ranked higher than
81% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 481.81 vs. MDXG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MDXG' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 6
Z-Score: 23.53
M-Score: -1.93
WACC vs ROIC
10.80%
46.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 12.15
MDXG's Operating margin (%) is ranked higher than
79% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. MDXG: 12.15 )
Ranked among companies with meaningful Operating margin (%) only.
MDXG' s Operating margin (%) Range Over the Past 10 Years
Min: -1334.98  Med: -19.79 Max: 6.01
Current: 12.15
-1334.98
6.01
Net-margin (%) 11.37
MDXG's Net-margin (%) is ranked higher than
80% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. MDXG: 11.37 )
Ranked among companies with meaningful Net-margin (%) only.
MDXG' s Net-margin (%) Range Over the Past 10 Years
Min: -1447.4  Med: -28.32 Max: 5.26
Current: 11.37
-1447.4
5.26
ROE (%) 22.08
MDXG's ROE (%) is ranked higher than
92% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MDXG: 22.08 )
Ranked among companies with meaningful ROE (%) only.
MDXG' s ROE (%) Range Over the Past 10 Years
Min: -276.61  Med: -113.28 Max: 7.64
Current: 22.08
-276.61
7.64
ROA (%) 18.01
MDXG's ROA (%) is ranked higher than
96% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. MDXG: 18.01 )
Ranked among companies with meaningful ROA (%) only.
MDXG' s ROA (%) Range Over the Past 10 Years
Min: -557.14  Med: -81.88 Max: 6.41
Current: 18.01
-557.14
6.41
ROC (Joel Greenblatt) (%) 76.25
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. MDXG: 76.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDXG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2458.54  Med: -847.17 Max: 39.25
Current: 76.25
-2458.54
39.25
Revenue Growth (3Y)(%) 111.50
MDXG's Revenue Growth (3Y)(%) is ranked higher than
100% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. MDXG: 111.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDXG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 293.6
Current: 111.5
0
293.6
» MDXG's 10-Y Financials

Financials (Next Earnings Date: 2016-02-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MDXG Guru Trades in Q1 2015

Steven Cohen 942,500 sh (New)
Paul Tudor Jones 38,800 sh (+103.16%)
Joel Greenblatt 61,414 sh (+70.38%)
Jim Simons 174,400 sh (-12.00%)
» More
Q2 2015

MDXG Guru Trades in Q2 2015

Jim Simons 581,500 sh (+233.43%)
Joel Greenblatt 56,809 sh (-7.50%)
Steven Cohen 834,300 sh (-11.48%)
Paul Tudor Jones 34,200 sh (-11.86%)
» More
Q3 2015

MDXG Guru Trades in Q3 2015

Jim Simons Sold Out
Steven Cohen 822,900 sh (-1.37%)
Paul Tudor Jones 29,700 sh (-13.16%)
Joel Greenblatt 47,930 sh (-15.63%)
» More
Q4 2015

MDXG Guru Trades in Q4 2015

Jim Simons 19,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 41.50
MDXG's P/E(ttm) is ranked lower than
71% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 26.20 vs. MDXG: 41.50 )
Ranked among companies with meaningful P/E(ttm) only.
MDXG' s P/E(ttm) Range Over the Past 10 Years
Min: 39.78  Med: 96.26 Max: 5530
Current: 41.5
39.78
5530
Forward P/E 15.38
MDXG's Forward P/E is ranked higher than
74% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 17.83 vs. MDXG: 15.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 42.14
MDXG's PE(NRI) is ranked lower than
75% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 27.30 vs. MDXG: 42.14 )
Ranked among companies with meaningful PE(NRI) only.
MDXG' s PE(NRI) Range Over the Past 10 Years
Min: 40.44  Med: 99.27 Max: 1843.33
Current: 42.14
40.44
1843.33
P/B 8.28
MDXG's P/B is ranked lower than
99.99% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. MDXG: 8.28 )
Ranked among companies with meaningful P/B only.
MDXG' s P/B Range Over the Past 10 Years
Min: 5.5  Med: 10.87 Max: 21.82
Current: 8.28
5.5
21.82
P/S 4.99
MDXG's P/S is ranked lower than
86% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. MDXG: 4.99 )
Ranked among companies with meaningful P/S only.
MDXG' s P/S Range Over the Past 10 Years
Min: 4.76  Med: 11.34 Max: 148
Current: 4.99
4.76
148
PFCF 54.24
MDXG's PFCF is ranked lower than
71% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 30.54 vs. MDXG: 54.24 )
Ranked among companies with meaningful PFCF only.
MDXG' s PFCF Range Over the Past 10 Years
Min: 52  Med: 69.43 Max: 221.2
Current: 54.24
52
221.2
POCF 37.95
MDXG's POCF is ranked lower than
76% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 19.47 vs. MDXG: 37.95 )
Ranked among companies with meaningful POCF only.
MDXG' s POCF Range Over the Past 10 Years
Min: 36.4  Med: 53.25 Max: 372
Current: 37.95
36.4
372
EV-to-EBIT 36.71
MDXG's EV-to-EBIT is ranked lower than
71% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 23.19 vs. MDXG: 36.71 )
Ranked among companies with meaningful EV-to-EBIT only.
MDXG' s EV-to-EBIT Range Over the Past 10 Years
Min: -619.4  Med: -8.40 Max: 1158.8
Current: 36.71
-619.4
1158.8
EV-to-EBITDA 32.82
MDXG's EV-to-EBITDA is ranked lower than
76% of the 292 Companies
in the Global Medical Devices industry.

( Industry Median: 16.58 vs. MDXG: 32.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDXG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -832.5  Med: -9.40 Max: 992.6
Current: 32.82
-832.5
992.6
Current Ratio 4.22
MDXG's Current Ratio is ranked higher than
70% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. MDXG: 4.22 )
Ranked among companies with meaningful Current Ratio only.
MDXG' s Current Ratio Range Over the Past 10 Years
Min: 0.05  Med: 1.57 Max: 7.08
Current: 4.22
0.05
7.08
Quick Ratio 3.99
MDXG's Quick Ratio is ranked higher than
75% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. MDXG: 3.99 )
Ranked among companies with meaningful Quick Ratio only.
MDXG' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 1.57 Max: 6.7
Current: 3.99
0.05
6.7
Days Inventory 91.69
MDXG's Days Inventory is ranked higher than
71% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. MDXG: 91.69 )
Ranked among companies with meaningful Days Inventory only.
MDXG' s Days Inventory Range Over the Past 10 Years
Min: 11.88  Med: 129.89 Max: 135.08
Current: 91.69
11.88
135.08
Days Sales Outstanding 97.55
MDXG's Days Sales Outstanding is ranked lower than
70% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. MDXG: 97.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDXG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.94  Med: 88.99 Max: 103.26
Current: 97.55
74.94
103.26
Days Payable 140.52
MDXG's Days Payable is ranked higher than
83% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. MDXG: 140.52 )
Ranked among companies with meaningful Days Payable only.
MDXG' s Days Payable Range Over the Past 10 Years
Min: 88.08  Med: 101.49 Max: 164.89
Current: 140.52
88.08
164.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 37.95
MDXG's Price/Net Cash is ranked lower than
82% of the 148 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDXG: 37.95 )
Ranked among companies with meaningful Price/Net Cash only.
MDXG' s Price/Net Cash Range Over the Past 10 Years
Min: 20.43  Med: 45.22 Max: 140
Current: 37.95
20.43
140
Price/Net Current Asset Value 10.69
MDXG's Price/Net Current Asset Value is ranked lower than
67% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 6.13 vs. MDXG: 10.69 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDXG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.35  Med: 26.06 Max: 147.5
Current: 10.69
11.35
147.5
Price/Tangible Book 9.61
MDXG's Price/Tangible Book is ranked lower than
76% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 4.13 vs. MDXG: 9.61 )
Ranked among companies with meaningful Price/Tangible Book only.
MDXG' s Price/Tangible Book Range Over the Past 10 Years
Min: 10.57  Med: 25.47 Max: 237.5
Current: 9.61
10.57
237.5
Price/Projected FCF 11.16
MDXG's Price/Projected FCF is ranked lower than
92% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 1.86 vs. MDXG: 11.16 )
Ranked among companies with meaningful Price/Projected FCF only.
MDXG' s Price/Projected FCF Range Over the Past 10 Years
Min: 14.19  Med: 26.24 Max: 354.5
Current: 11.16
14.19
354.5
Price/Median PS Value 0.44
MDXG's Price/Median PS Value is ranked higher than
87% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 0.96 vs. MDXG: 0.44 )
Ranked among companies with meaningful Price/Median PS Value only.
MDXG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.56  Med: 1.01 Max: 12.27
Current: 0.44
0.56
12.27
Price/Graham Number 4.24
MDXG's Price/Graham Number is ranked lower than
72% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.68 vs. MDXG: 4.24 )
Ranked among companies with meaningful Price/Graham Number only.
MDXG' s Price/Graham Number Range Over the Past 10 Years
Min: 0.46  Med: 2.74 Max: 24.59
Current: 4.24
0.46
24.59
Earnings Yield (Greenblatt) (%) 2.70
MDXG's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. MDXG: 2.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDXG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.20 Max: 2.79
Current: 2.7
0.1
2.79

More Statistics

Revenue(Mil) $175
EPS $ 0.18
Beta1.19
Short Percentage of Float20.17%
52-Week Range $6.71 - 13.20
Shares Outstanding(Mil)108.96

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 187 259 319 366
EPS($) 0.33 0.36 0.48 0.59
EPS without NRI($) 0.33 0.36 0.48 0.59

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:MXE.Germany,
MiMedx Group Inc was incorporated in Florida on February 28, 2008. The Company develops clinical solutions for the use of its biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied approximately over 200,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. Its technology and products are Purion, AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. The Company operates a licensed tissue bank. Its solutions are being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds.
» More Articles for NAS:MDXG

Headlines

Articles On GuruFocus.com
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
MiMedx to Present at the RBC Capital Markets' 2016 Global Healthcare conference Feb 11 2016
MiMedx Announces Release Date For 2015 Full Year Results Feb 10 2016
Medical Appliances & Equipment Equities Ahead of Market -- ResMed, ZELTIQ Aesthetics, MiMedx Group,... Feb 03 2016
MIMEDX GROUP ALERT – Andrews & Springer LLC Announces Update in the Securities Fraud Lawsuit... Jan 25 2016
MIMEDX GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Jan 13 2016
MiMedx Completes Acquisition Of Stability Biologics Jan 13 2016
Edited Transcript of MDXG earnings conference call or presentation 11-Jan-16 2:30pm GMT Jan 12 2016
MiMedx Group Inc Earnings and Agreement To Acquire Stability Biologics Call scheduled for 9:30 am ET... Jan 11 2016
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 11 2016
MiMedx Group, Inc. breached its 50 day moving average in a Bearish Manner : January 11, 2016 Jan 11 2016
MiMedx signs definitive agreement to acquire Stability Biologics Jan 10 2016
MiMedx Exceeds Fourth Quarter And Full Year 2015 Revenue Consensus Jan 10 2016
MiMedx Signs Definitive Agreement To Acquire Stability Biologics Jan 10 2016
MiMedx Receives Certificate From FDA Allowing The Export Of MiMedx Allografts Jan 06 2016
MiMedx To Present At 34th Annual J.P. Morgan Healthcare Conference Dec 28 2015
MiMedx Addresses Numerous False Statements in Recent Short Seller Newsletter Dec 23 2015
One Hundred patient multi-center Comparative Study of MiMedx Epifix® and Organogenesis Apligraf®... Dec 23 2015
[$$] 5 Small Stocks That Can Shoot Higher in January Dec 17 2015
MiMedx Provides 2016 Guidance With Forecasted Revenue Growth In Excess Of 30% And Operating Earnings... Dec 16 2015
MiMedx Group, Inc. breached its 50 day moving average in a Bearish Manner : December 10, 2015 Dec 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK